Agilent Technologies (A) Leans Into Digital Pathology On An Undervalued Narrative
Agilent Technologies (A) has drawn fresh investor attention after securing FDA clearance and launching its S540MD Slide Scanner System in the U.S., a whole slide imaging platform designed for high-throughput digital pathology workflows.
These product launches and the raised full year 2026 revenue guidance come as Agilent Technologies’ recent share price momentum has been positive, with a 30 day share price return of 6.91% and a 90 day share price return of 11.39%. The 1 year total shareholder return of 18.11% points to building interest over a longer horizon.
Scan other high-throughput and AI-ready lab suppliers moving on similar trends with Agilent Technologies by reviewing the hand-picked 36 robotics and automation stocks in our screener.
Agilent Technologies has advanced on solid earnings, higher 2026 guidance, and fresh product launches, yet the stock still trades at a discount to one common intrinsic value estimate. Does it make more sense to step in now or wait for a better entry?
Most Popular Narrative: 13.7% Undervalued
Agilent Technologies last closed at $150.86, compared with a most popular narrative fair value of $174.90, which points to a valuation gap that analysts are trying to explain through earnings, margin and growth assumptions.
Strategic investments in higher-margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.
Want to see what sits behind that fair value for Agilent Technologies? The narrative leans on faster compound revenue, wider margins and a richer earnings multiple. Curious which specific profit and cash flow paths justify that price tag.
Result: Fair Value of $174.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in risks for Agilent Technologies, including higher tariff related costs, as well as any prolonged funding pressure in academic and government labs.
Find out about the key risks to this Agilent Technologies narrative.
Another View on Agilent Technologies: What the P/E Ratio Signals
Agilent Technologies looks inexpensive compared with one fair value estimate, yet its current P/E of 29.5x is higher than a fair ratio of 26.2x that the market could move toward. That gap points to some valuation risk even though the P/E is lower than global Life Sciences peers at 36.6x and the peer group at 36x. How comfortable are you paying a richer multiple today when other companies in the sector offer similar growth on lower implied expectations?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment split between undervaluation potential and richer P/E risks, it helps to inspect the numbers yourself and decide quickly how Agilent Technologies fits your approach. To understand what investors are optimistic about in more depth, start with the 3 key rewards.
Looking for more investment ideas beyond Agilent Technologies?
If you stop with Agilent Technologies, you might miss other opportunities that match your style. Use the Simply Wall Street Screener to widen your options confidently.
- Target income first and review companies with reliable payouts using the 11 dividend fortresses.
- Seek value and hunt for potential bargains across the market with the 47 high quality undervalued stocks.
- Prioritise resilience and stress test your portfolio with the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com